Skip to main content

Table 2 Analysis of raw odds ratio

From: Association of frailty with endothelial dysfunction and its possible impact on negative outcomes in Brazilian predialysis patients with chronic kidney disease

Variables

OR

P value

IC 95 %

Female

3.41

0.03

1.17

9.93

>60 years

3.00

0.04

1.03

8.73

Overweight (BMI: 25 – 29.9 kg/m2)

1.48

0.53

0.43

5.10

Obese (BMI ≥ 30 kg/m2)

3.06

0.10

0.82

11.44

Abdominal circunference (H ≥ 94 cm; M ≥ 80 cm)

2.48

0.14

0.75

8.18

Anemia (Hb ≤ 11 g/dL)

1.39

0.71

0.25

7.52

Glycemia (100 mg/dL)

1.81

0.29

0.60

5.40

Phosphorusa

0.24

0.21

0.02

2.19

Calcium (8,4 a 9,5 mg/dL)

0.77

0.63

0.28

2.17

iPTHb

1.62

0.47

0.43

6.14

TSH (4,0 μUI/mL)

2.00

0.43

0.36

11.23

Serum albumin (3,5 mg/dL)

2.00

0.19

0.70

5.69

Total cholesterol (200 mg/dL)

1.28

0.66

0.42

3.96

LDL-c (130 mg/dL)

1.09

0.91

0.26

4.54

HDL-c (H ≥ 60 mg/dL; M ≥ 50 mg/dL)

0.64

0.42

0.22

1.88

TGL (150 g/dL)

0.79

0.67

0.28

2.28

TSAT (≥20 %)

0.51

0.41

0.10

2.53

Ferritin (≤100 ng/dL)

0.62

0.38

0.22

1.79

HCO3 (22 mmol/L)

1.02

0.97

0.37

2.85

FMD (dif ≥10 %)

2.83

0.05

0.99

8.13

TNF-α (pg/ml) c

1.16

0.79

0.39

3.39

IL-6 (pg/ml) d

1.25

0.49

0.66

2.35

  1. aP (Stages 3 and 4: 2.7 to 4.6 mg/dL, Stage 5: 3.5 to 5.5 mg/dL)
  2. biPTH (Stage 3: 35 a 70 pg/ml, Stage 4: 70 a 110 pg/ml, Stage 5: 110 to 300 pg/ml)
  3. cTNF-α (<6.83 pg/ml; 6.83–19.22 pg/ml; >19.22 pg/ml)
  4. dIL-6 (<2.13 pg/ml; 2.13–3.9 pg/ml; >3.9 pg/ml)
  5. FMD flow-mediated vasodilatation